Abstract 418P
Background
Mutational landscape studies, facilitated by next-generation sequencing technologies, can improve our understanding of cancer pathogenesis and help identify potentially targetable alterations. In this study, we aimed to provide an overall description of the mutational landscape in non-small cell lung cancer (NSCLC) using publicly available sequencing data.
Methods
We used the American Association for Cancer Research’s Project Genomics Evidence Neoplasia Information Exchange (GENIE) [GENIE Cohort v11.0-public study] to obtain sequencing data for patients diagnosed with NSCLC. Mutational profiles were described according to race (White, Black, or Asian) and histopathology (adenocarcinoma or squamous cell carcinoma). We used the OncoKB to assess the actionability of frequently mutated genes in the studied cohort.
Results
We included 16,498 samples (13,927 White, 1,304 Black, and 1,267 Asian; 12,790 adenocarcinoma, and 1,546 squamous cell carcinoma). TP53 was the most frequently mutated gene, with half of the analyzed samples (49.6%) containing at least one TP53-related molecular alteration. TP53 mutation rate was higher in cases with squamous cell carcinoma compared to cases with adenocarcinoma (76.7% vs. 45.6%; p<0.001). In race-dependent subgroup analysis, mutations in EGFR gene occurred in about 53.3% of Asian cases to rank as the most frequently mutated gene in this subgroup (Table). Most of the frequently mutated genes in NSCLC (especially in the squamous cell carcinoma subgroup) are still not actionable (Table). Table: 418P
Commonly mutated genes in NSCLC
Adenocarcinoma | Squamous Cell | White | Black | Asian |
TP53 (45.6%) | TP53 (76.6%) | TP53 (49.2%) | TP53 (55.7%) | EGFR (53.3%) * |
KRAS (32.2%) * | KMT2D (22.1%) | KRAS (30%) * | PCM1 (25%) | TP53 (48.2%) |
EGFR (25.8%) * | PRKDC (11.5%) | EGFR (18.8%) * | KRAS (24.8%) * | KRAS (10.6%) * |
KEAP1 (13.5%) | PCM1 (11.3%) | KEAP1 (14.6%) | EGFR (20.6%) * | RBM10 (9.5%) |
SKT11 (13.1%) * | KEAP1 (11%) | LRP1B (13%) | KEAP1 (11.8%) | KMT2D (6.9%) |
* gene with actionable mutation(s)
Conclusions
Despite progress in the targetability of NSCLC, many of the most frequently mutated genes are still not actionable. Genomic profiling has the potential to identify potential targets of interest, which could guide individualized treatment plans to address the current high burden of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06